Promising antitumour activity presented for emerging targets in different solid tumours
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Drug Rediscovery Protocol-like Clinical Trials facilitate access to precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types
Rising rates of cancer in young people: nature or nurture?
High-quality studies employing molecular pathological epidemiology frameworks could help pinpoint aetiologic mechanisms and help tackle a potential future epidemic among the youngest
Pioneering the future of immunotherapy: new targets, novel strategies
Several studies report on promising data with immunomodulation and alternative approaches
Pre-operative immunoradiation shows clinical benefit in patients with high-risk, early-stage breast cancer
Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy
Early-phase studies show therapeutic potential of oncolytic viruses across cancer types
However, presented findings raise some questions about their efficacy in non-injected lesions and the durability of responses
Multi-cancer early detection – promise or reality?
While there has been significant progress in the development of these blood tests, hurdles remain including test sensitivity and false positives
Claudin-targeted antibody–drug conjugates are promising treatments for solid tumours
According to results from several phase I trials, this precision oncology strategy also offers manageable safety
Does artificial intelligence have a place in precision oncology?
Applications in artificial intelligence have the potential to transform precision oncology, but data quality and clinical validation of tools are still challenging
KRAS and TP53 may have a key role in the development of pancreatic cancer
Studies provide new insights into the driver landscape of these gastrointestinal tumours and show improved prediction of patient-specific outcomes.